Top 10 Immunology Drugs by 2026 Revenue: Dupixent, Skyrizi and Rinvoq Lead

Rank	Brand	Indications	H1 Revenues (in billions)	2026 Revenues (in billions)
1	Dupixent	Atopic dermatitis, Asthma, CRSwNP, Eosinophilic esophagitis, Prurigo nodularis	$10.7
2	Skyrizi	Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis	$10.0
3	Rinvoq	Rheumatoid arthritis, Psoriatic arthritis, Atopic dermatitis, Ulcerative colitis, Crohn's disease, Ankylosing spondylitis, nr-axSpA	$4.6
4	Tremfya	Plaque psoriasis, Psoriatic arthritis, Ulcerative colitis	$3.6
5	Cosentyx	Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis, nr-axSpA, Enthesitis-related arthritis, Hidradenitis suppurativa	$3.4
6	Entyvio	Ulcerative colitis, Crohn's disease	$3.0
7	Orencia	Rheumatoid arthritis, Polyarticular JIA, Psoriatic arthritis, aGVHD prophylaxis	$1.9
8	Nucala	Severe eosinophilic asthma, EGPA, Hypereosinophilic syndrome, CRSwNP	$1.5
9	Benlysta	Systemic lupus erythematosus (SLE), Lupus nephritis	$1.2
10	Fasenra	Severe Eosinophilic Asthma, Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)	$1.0

The global immunology market continues to expand as biologic medicines move into more disease areas, gain pediatric approvals, and compete across dermatology, gastroenterology, rheumatology, respiratory medicine, and autoimmune care.

Market overview

The ranking reveals a clear concentration of commercial power.

In the first half of 2026, Dupixent and Skyrizi together generated $20.7 billion, accounting for slightly more than half of the combined revenue of the 10 products.

The market is also highly concentrated by therapeutic area.

• Dermatology remains a major revenue engine, with Dupixent, Skyrizi, Rinvoq, Tremfya, and Cosentyx all competing in inflammatory skin diseases.

• Gastroenterology is another important growth area, supported by Skyrizi, Tremfya, and Entyvio.

• Respiratory and eosinophilic diseases are represented by Dupixent, Nucala, and Fasenra.

• Autoimmune rheumatology remains central to the commercial profile of Rinvoq, Orencia, Skyrizi, Tremfya, and Cosentyx.

1. Dupixent leads the market

Dupixent ranked first with reported first-half revenue of $10.7 billion. The product generated €9.324 billion in net sales during the first six months of 2026, representing growth of 27.5% on a reported basis and 34.4% at constant exchange rates.

The brand’s performance was supported by volume growth across its approved indications. Its commercial reach now extends across several immune-mediated diseases, including: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, and allergic fungal rhinosinusitis.

The United States remained the largest regional market, with first-half sales of €6.922 billion and constant-currency growth of 39.5%. Europe contributed €1.146 billion, while the rest of the world generated €1.256 billion.

Dupixent also expanded its regulatory reach during the period. The US FDA approved the medicine for adults and children aged six years and older with allergic fungal rhinosinusitis who have a history of sinonasal surgery.

The FDA and European Commission also authorized its use in children aged two to 11 years with chronic spontaneous urticaria that remains symptomatic despite H1 antihistamine treatment. Japan approved the medicine for adults with moderate-to-severe bullous pemphigoid.

The breadth of its indications gives Dupixent a major commercial advantage. Rather than relying on one disease area, the product operates across dermatology, respiratory medicine, gastroenterology, and allergic disease.

2. Skyrizi approaches $21+ billion in 2026

Skyrizi ranked second with H1 revenue of $10.0 billion. The product generated $8.5 billion in the United States and $1.5 billion outside the country.

Its core indications include plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The brand’s growth strategy is built around expansion in inflammatory bowel disease and continued strength in dermatology.

Skyrizi is also positioned as a major replacement product following the loss of exclusivity of Humira. Its uptake in gastroenterology, convenient dosing, and strong clinical performance have supported expansion across markets.

In February 2026, positive Phase 3 AFFIRM results supported the evaluation of subcutaneous induction therapy for adults with moderately to severely active Crohn’s disease. AbbVie submitted a related application to the FDA in April.

The product also received pediatric regulatory progress in 2026. The European Commission approved Skyrizi for children aged six years and older with moderate-to-severe plaque psoriasis who are candidates for systemic treatment. The FDA approved the medicine for children in the same age group with plaque psoriasis and for pediatric patients with active psoriatic arthritis.

Skyrizi’s commercial profile demonstrates the value of combining dermatology and gastroenterology indications. Inflammatory bowel disease provides a large expansion opportunity, while psoriasis continues to support the product’s base business.

3. Rinvoq builds a broad immunology franchise

Rinvoq generated $4.6 billion in first-half revenue and ranked third among the products assessed.

The medicine is approved across a wide range of immune-mediated conditions, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Its broad indication base helps reduce reliance on a single therapeutic market. Rinvoq competes across rheumatology, dermatology, and gastroenterology, placing it in several of the fastest-growing areas of immunology.

AbbVie submitted applications in 2026 for potential new uses in non-segmental vitiligo and severe alopecia areata. If approved, these indications could extend the product into additional dermatology markets.

The brand’s key commercial challenge is competition within the Janus kinase inhibitor category and the need to manage safety considerations associated with the class. Its future growth will depend on sustained efficacy, successful lifecycle expansion, and continued physician confidence across its approved indications.

4. Tremfya gains momentum in inflammatory disease

Tremfya generated approximately $3.6 billion in first-half sales and ranked fourth. Separate company reporting cited revenue of about $3.7 billion, including $2.5 billion from the United States. The slight difference reflects the figures and reporting periods supplied.

The product is approved for plaque psoriasis, psoriatic arthritis, and inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.

Tremfya has become a significant growth product in gastroenterology. Its sales growth in Crohn’s disease and ulcerative colitis has been particularly strong, while the brand has continued to gain share in psoriasis and psoriatic arthritis.

During the second quarter, the product received approval related to inhibition of structural damage in psoriatic arthritis. This development may strengthen its position in a market where long-term disease modification is increasingly important.

Tremfya’s expansion into inflammatory bowel disease gives it a broader growth profile than a traditional psoriasis medicine. The main commercial opportunity is to convert its dermatology presence into a larger gastroenterology franchise.

5. Cosentyx remains a diversified immunology brand

Cosentyx recorded $3.4 billion in first-half revenue and ranked fifth.

Its approved treatment areas include plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa.

US performance supported sales growth, including expansion in hidradenitis suppurativa and intravenous treatment use. Outside the United States, Europe and several emerging markets contributed to growth, although weaker performance in China partly offset those gains.

The product also generated encouraging results in the Phase 3 REPLENISH study in polymyalgia rheumatica. Cosentyx produced statistically significant sustained remission at Week 52 compared with placebo and doubled remission rates while reducing cumulative exposure to glucocorticoids.

Cosentyx benefits from a diversified inflammatory disease portfolio, but future growth will depend on maintaining momentum in hidradenitis suppurativa, expanding use in intravenous treatment, and securing additional indications.

6. Entyvio strengthens its gastrointestinal position

Entyvio ranked sixth with H1 revenue of $3.0 billion. The product is focused on ulcerative colitis and Crohn’s disease.

Takeda reported second-quarter sales of JPY 268.3 billion, representing growth of 15.4% at actual exchange rates and 3.8% at constant exchange rates. US sales reached JPY 169.5 billion, while European sales totaled JPY 63.5 billion.

Growth was supported by the subcutaneous formulation and continued patient uptake. In Europe, the subcutaneous version also contributed to higher patient numbers.

Entyvio is pursuing further expansion in pediatric inflammatory bowel disease. In June 2026, the FDA accepted a supplemental application for intravenous Entyvio in children aged two years and older with moderately to severely active ulcerative colitis or Crohn’s disease.

Takeda also submitted an application to European regulators for the pediatric use. The filings are supported by the Phase 3 KEPLER trial in ulcerative colitis and the ongoing WEBB study in Crohn’s disease.

In Japan, Takeda submitted an application for a four-week maintenance dosing option for adults who experience reduced response during treatment. The company also sought pediatric dosing expansion for ulcerative colitis and Crohn’s disease.

Entyvio’s next growth phase will depend on pediatric expansion, wider use of the subcutaneous formulation, and the ability to retain patients in an increasingly competitive inflammatory bowel disease market.

7. Orencia remains established in autoimmune care

Orencia generated $1.9 billion in first-half revenue and ranked seventh.

Its treatment areas include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and prophylaxis against acute graft-versus-host disease.

Compared with the leading products in the ranking, Orencia has a more established and concentrated commercial profile. However, its long-standing presence in autoimmune disease and use in both adult and pediatric populations provide a durable revenue base.

Its inclusion in acute graft-versus-host disease prophylaxis also gives the brand exposure to a specialized hematology and transplant setting. This diversification may help support demand beyond rheumatology.

8. Nucala targets eosinophilic disease

Nucala generated $1.5 billion in first-half revenue and ranked eighth.

The medicine is used in severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps.

Its positioning is centered on eosinophil-driven inflammatory disease. That focus gives Nucala a clear specialist identity, particularly in severe respiratory disease and rare eosinophilic disorders.

Nucala competes directly and indirectly with broader immunology brands that are expanding into asthma and nasal disease.

9. Benlysta expands lupus treatment

Benlysta generated $1.2 billion in first-half revenue and ranked ninth.

Its approved treatment areas include systemic lupus erythematosus and lupus nephritis. These indications place Benlysta in a market with substantial unmet need and a large global patient population.

Lupus treatment is becoming more focused on reducing disease activity, preventing organ damage, and limiting long-term reliance on corticosteroids. Benlysta’s presence in both systemic lupus and lupus nephritis gives it exposure to general autoimmune care and kidney-related complications.

Benlysta's challenge is competition from emerging targeted medicines and the complexity of diagnosing and monitoring lupus patients.

10. Fasenra completes the top 10

Fasenra recorded $1.0 billion in first-half revenue and ranked tenth.

The medicine is used in severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.

Like Nucala, Fasenra is focused on eosinophilic inflammatory disease. This specialization allows it to target patients with severe disease who may require biologic treatment after conventional therapies fail to provide adequate control.

Immunology market trends

Dermatology remains a growth engine

Atopic dermatitis and psoriasis account for a substantial share of the revenue generated by the leading immunology medicines. Dupixent, Skyrizi, Rinvoq, Tremfya, and Cosentyx all have important roles in dermatology.

The market is moving beyond basic symptom control. Treatment competition increasingly focuses on disease severity, long-term control, quality of life, speed of response, and persistence.

Gastroenterology is expanding rapidly

Crohn’s disease and ulcerative colitis are major growth markets for Skyrizi, Tremfya, and Entyvio. Rinvoq also benefits from its presence in inflammatory bowel disease.

The commercial shift reflects a broader move toward advanced therapies earlier in treatment pathways. Companies are also investing in formulations, dosing schedules, and pediatric indications to improve patient access and retention.

Eosinophilic diseases are attracting competition

Severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps are served by Nucala, Fasenra, and Dupixent.

Frequently asked questions

What is the top-selling immunology drug in H1 2026?

Dupixent ranked first with reported first-half revenue of $10.7 billion.

Which immunology drugs generated more than $10 billion?

Dupixent and Skyrizi were the two products in the ranking with first-half revenue of approximately $10 billion or more.

Which immunology drug has the broadest indication portfolio?

Rinvoq has one of the broadest portfolios in the ranking, covering rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Which immunology medicines are used for inflammatory bowel disease?

Skyrizi, Rinvoq, Tremfya, and Entyvio are included in the ranking for Crohn’s disease, ulcerative colitis, or both.

Which medicines target eosinophilic diseases?

Dupixent, Nucala, and Fasenra are used across conditions involving eosinophilic inflammation, including severe eosinophilic asthma and related disorders.

What is driving immunology drug growth?

The main growth drivers are new indications, expansion into inflammatory bowel disease, pediatric approvals, greater use of biologic treatment, improved diagnosis, new formulations, and broader access to advanced therapies.